
Topics Included: Artificial Intelligence
SHARE TO:
Hybrid Public Workshop Resources:
Meeting Recordings:
Welcome & Session 1: Where Are We Now?
Session 2: Data Quality, Reliability, Representativeness, and Access in AI-Driven Drug Development
Session 3: Model Performance, Explainability, Transparency, and Interpretability in AI-Driven Drug Development
Session 4: Navigating the Future of AI in Drug Development
Discussion & Concluding Remarks
Share Your Feedback
We welcome your questions and feedback about this workshop. If you have follow-up thoughts or comments on the topics discussed, please share them using the brief form linked below. Your input will help inform future discussions and events.
Recent News Feed
- Designing Trials for the Data We’ll Need Next: Dana Lewis on Participant Burden, Researcher Burden, and Consent in the AI Era April 22, 2026

- Holiday Greetings from CTTI: Bridging Vision and Impact in 2025 December 10, 2025

- FDA, CTTI Convening 2025 Hybrid Public Workshop on Artificial Intelligence in Drug & Biological Product Development August 25, 2025

